Kala Bio (KALA) EBT Margin (2019 - 2022)
Kala Bio (KALA) posted EBT Margin of 3757.62% for Q3 2022, down 180.71% sequentially from 1338.62% in Q2 2022, and down 283577.0% YoY from N/an in Q3 2021.
Kala Bio (KALA) EBT Margin (2019 - 2022) Analysis & Trends
Kala Bio has reported EBT Margin for 4 years, with the latest figure at 3757.62% in Q3 2022.
- Quarterly EBT Margin fell 283577.0% year-over-year to 3757.62% in Q3 2022, while the trailing twelve-month figure through Dec 2022 was 2235.35% (down 99358.0% YoY) and the FY2022 annual result came in at 5201.64%, down 293942.0% from the prior year.
- EBT Margin slipped to 3757.62% in Q3 2022 per KALA's latest filing, from 1338.62% in the prior quarter.
- Over five years, EBT Margin peaked at 921.85% in Q3 2021 and troughed at 7401.32% in Q2 2020.
- A 4-year average of 2207.87% and a median of 1831.75% in 2019 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2020 and 2021: EBT Margin sank 586078 bps in 2020, then jumped 637772 bps in 2021.
- Over 4 years, EBT Margin stood at 1838.64% in 2019, then climbed by 22 bps to 1425.11% in 2020, then plunged by 85 bps to 2637.55% in 2021, then slumped by 42 bps to 3757.62% in 2022.
- According to Business Quant data, EBT Margin over the past three periods registered 3757.62%, 1338.62%, and 2400.95% for Q3 2022, Q2 2022, and Q1 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -3,757.62% |
| Jun 30, 2022 | -1,338.62% |
| Mar 31, 2022 | -2,400.95% |
| Dec 31, 2021 | -2,637.55% |
| Sep 30, 2021 | -921.85% |
| Jun 30, 2021 | -1,023.60% |
| Mar 31, 2021 | -952.82% |
| Dec 31, 2020 | -1,425.11% |
| Sep 30, 2020 | -2,106.04% |
| Jun 30, 2020 | -7,401.32% |
| Mar 31, 2020 | -2,204.39% |
| Dec 31, 2019 | -1,838.64% |
| Sep 30, 2019 | -1,737.22% |
| Jun 30, 2019 | -1,540.54% |
| Mar 31, 2019 | -1,831.75% |